(DRTS) Alpha Tau Medical - Overview
Exchange: NASDAQ •
Country: Israel •
Currency: USD •
Type: Common Stock •
ISIN: IL0011839383
Stock:
Total Rating 48
Risk 80
Buy Signal 2.75
| Risk 5d forecast | |
|---|---|
| Volatility | 134% |
| Relative Tail Risk | -13.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.05 |
| Alpha | 191.75 |
| Character TTM | |
|---|---|
| Beta | 0.859 |
| Beta Downside | 1.132 |
| Drawdowns 3y | |
|---|---|
| Max DD | 57.42% |
| CAGR/Max DD | 0.62 |
Description: DRTS Alpha Tau Medical
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers. The company is headquartered in Jerusalem, Israel.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.21 > 0.02 and ΔFCF/TA 5.81 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.19 > 3% & CFO -19.8m > Net Income -40.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.43 > 1.5 & < 3 |
| Outstanding Shares: last quarter (85.3m) vs 12m ago 21.98% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -47.68 > 6 (EBITDA TTM -34.3m / Interest Expense TTM 344.0k) |
Altman Z'' -9.31
| A: 0.65 (Total Current Assets 77.1m - Total Current Liabilities 9.14m) / Total Assets 104.7m |
| B: -1.70 (Retained Earnings -178.0m / Total Assets 104.7m) |
| C: -0.17 (EBIT TTM -16.4m / Avg Total Assets 97.7m) |
| D: -6.57 (Book Value of Equity -178.0m / Total Liabilities 27.1m) |
| Altman-Z'' Score: -9.31 = D |
Beneish M
| DSRI: none (Receivables 332.0k/1.36m, Revenue 0.0/0.0) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.93 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: none (Revenue 0.0 / 0.0) |
| TATA: -0.19 (NI -40.0m - CFO -19.8m) / TA 104.7m) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of DRTS shares?
As of February 26, 2026, the stock is trading at USD 8.42 with a total of 936,661 shares traded.
Over the past week, the price has changed by +15.03%, over one month by +14.87%, over three months by +115.90% and over the past year by +214.18%.
Over the past week, the price has changed by +15.03%, over one month by +14.87%, over three months by +115.90% and over the past year by +214.18%.
Is DRTS a buy, sell or hold?
Alpha Tau Medical has received a consensus analysts rating of 4.50.
Therefore, it is recommended to buy DRTS.
- StrongBuy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DRTS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.3 | -2% |
| Analysts Target Price | 8.3 | -2% |
DRTS Fundamental Data Overview February 21, 2026
P/B = 7.9237
Revenue TTM = 0.0 USD
EBIT TTM = -16.4m USD
EBITDA TTM = -34.3m USD
Long Term Debt = 6.15m USD (from longTermDebt, last quarter)
Short Term Debt = 1.12m USD (from shortTermDebt, last quarter)
Debt = 13.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.2m USD (from netDebt column, last quarter)
Enterprise Value = 558.6m USD (617.3m + Debt 13.5m - CCE 72.2m)
Interest Coverage Ratio = -47.68 (Ebit TTM -16.4m / Interest Expense TTM 344.0k)
EV/FCF = -25.37x (Enterprise Value 558.6m / FCF TTM -22.0m)
FCF Yield = -3.94% (FCF TTM -22.0m / Enterprise Value 558.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.10m) / Revenue TTM)
Tobins Q-Ratio = 5.34 (Enterprise Value 558.6m / Total Assets 104.7m)
Interest Expense / Debt = 2.55% (Interest Expense 344.0k / Debt 13.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -13.0m (EBIT -16.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.43 (Total Current Assets 77.1m / Total Current Liabilities 9.14m)
Debt / Equity = 0.17 (Debt 13.5m / totalStockholderEquity, last quarter 77.6m)
Debt / EBITDA = -0.30 (negative EBITDA) (Net Debt 10.2m / EBITDA -34.3m)
Debt / FCF = -0.46 (negative FCF - burning cash) (Net Debt 10.2m / FCF TTM -22.0m)
Total Stockholder Equity = 70.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -40.90% (Net Income -40.0m / Total Assets 104.7m)
RoE = -56.45% (Net Income TTM -40.0m / Total Stockholder Equity 70.8m)
RoCE = -21.32% (EBIT -16.4m / Capital Employed (Equity 70.8m + L.T.Debt 6.15m))
RoIC = -16.92% (negative operating profit) (NOPAT -13.0m / Invested Capital 76.6m)
WACC = 8.93% (E(617.3m)/V(630.8m) * Re(9.08%) + D(13.5m)/V(630.8m) * Rd(2.55%) * (1-Tc(0.21)))
Discount Rate = 9.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.62%
[DCF] Fair Price = unknown (Cash Flow -22.0m)
EPS Correlation: 8.29 | EPS CAGR: 184.0% | SUE: 1.25 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.12 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.48 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=+6.3% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
Revenue TTM = 0.0 USD
EBIT TTM = -16.4m USD
EBITDA TTM = -34.3m USD
Long Term Debt = 6.15m USD (from longTermDebt, last quarter)
Short Term Debt = 1.12m USD (from shortTermDebt, last quarter)
Debt = 13.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.2m USD (from netDebt column, last quarter)
Enterprise Value = 558.6m USD (617.3m + Debt 13.5m - CCE 72.2m)
Interest Coverage Ratio = -47.68 (Ebit TTM -16.4m / Interest Expense TTM 344.0k)
EV/FCF = -25.37x (Enterprise Value 558.6m / FCF TTM -22.0m)
FCF Yield = -3.94% (FCF TTM -22.0m / Enterprise Value 558.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.10m) / Revenue TTM)
Tobins Q-Ratio = 5.34 (Enterprise Value 558.6m / Total Assets 104.7m)
Interest Expense / Debt = 2.55% (Interest Expense 344.0k / Debt 13.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -13.0m (EBIT -16.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.43 (Total Current Assets 77.1m / Total Current Liabilities 9.14m)
Debt / Equity = 0.17 (Debt 13.5m / totalStockholderEquity, last quarter 77.6m)
Debt / EBITDA = -0.30 (negative EBITDA) (Net Debt 10.2m / EBITDA -34.3m)
Debt / FCF = -0.46 (negative FCF - burning cash) (Net Debt 10.2m / FCF TTM -22.0m)
Total Stockholder Equity = 70.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -40.90% (Net Income -40.0m / Total Assets 104.7m)
RoE = -56.45% (Net Income TTM -40.0m / Total Stockholder Equity 70.8m)
RoCE = -21.32% (EBIT -16.4m / Capital Employed (Equity 70.8m + L.T.Debt 6.15m))
RoIC = -16.92% (negative operating profit) (NOPAT -13.0m / Invested Capital 76.6m)
WACC = 8.93% (E(617.3m)/V(630.8m) * Re(9.08%) + D(13.5m)/V(630.8m) * Rd(2.55%) * (1-Tc(0.21)))
Discount Rate = 9.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.62%
[DCF] Fair Price = unknown (Cash Flow -22.0m)
EPS Correlation: 8.29 | EPS CAGR: 184.0% | SUE: 1.25 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.12 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.48 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=+6.3% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)